Literature DB >> 3826213

Treatment of acute intrapartum fetal distress by beta 2-sympathomimetics.

C Mendez-Bauer, A Shekarloo, V Cook, U Freese.   

Abstract

Patients with a diagnosis of severe intrapartum fetal distress by fetal heart rate and capillary blood pH monitoring received beta 2-sympathomimetics to inhibit uterine contractions (tocolysis) while the obstetric team was preparing to deliver the fetus. Fetal heart rate and acidosis significantly improved after tocolysis; these fetuses were subsequently delivered in very good metabolic and clinical condition. The favorable effect of tocolysis on fetal homeostasis is attributed to the suppression of the ischemic effect of contractions on the placental circulation. The few fetuses having an extremely compromised placental function showed no improvement in heart rate or acidosis with tocolysis and were immediately delivered. Considering the mild side effects observed, the lack of maternal complications, and the remarkable perinatal outcome obtained, we recommend using tocolysis before delivering distressed fetuses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3826213     DOI: 10.1016/0002-9378(87)90067-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Uterine relaxation can be life saving.

Authors:  S H Rolbin; E M Hew; A Bernstein
Journal:  Can J Anaesth       Date:  1991-10       Impact factor: 5.063

2.  Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants.

Authors:  Z Weintraub; M Solovechick; B Reichman; A Rotschild; D Waisman; O Davkin; A Lusky; Y Bental
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

3.  Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.

Authors:  Tsuyoshi Murata; Hyo Kyozuka; Shun Yasuda; Toma Fukuda; Teruyoshi Tanaka; Keiya Fujimori
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.